Daratumumab monotherapy in patients with treatment-refractory multiple myeloma (SIRIUS): an open-label, randomised, phase 2 trial.

By S. Lonial, B. Weiss, S. Usmani, S. Singhal, A. Chari, N. Bahlis, A. Belch, A. Krishnan, R. Vescio, M. Mateos and 22 more. The Lancet, 2016

777 citations recorded by the source corpus.

View Paper: https://www.semanticscholar.org/paper/bc7eaea3b3063a6717b97a2a163753e56ffa5dcd

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

1. S. Rajkumar

Citations in the corpus

• Multiple myeloma: 2020 update on diagnosis, risk‐stratification and management (2020, background): “In a phase II trial, daratumumab as a single-agent was produced a response rate of approximately 30% in heavily pretreated patients.(85) Based on these findings, daratumumab was first granted accelerated approval by the FDA in 2015 for the treatment of patients with multiple myeloma who have receive”